Apolinário et al. [22] recently investigated the impact of tocilizumab (TCZ), a known rheumatoid arthritis (RA) drug which inhibits IL-6-mediated pro-inflammatory activity, using an antibody with specificity for soluble and membrane-expressed IL-6R. Here, IL6R is linked to rheumatoid arthritis.